Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
Gold surged to its highest level in nearly six years on Monday as the prospects of lower Federal Reserve rates and lingering geopolitical tensions between the U.S. and Iran...Marketsread more
Amazon announces the opening of the Amazon Professional Beauty Store to offer professional stylists, barbers and aestheticians beauty supplies typically found in salons and...Marketsread more
Bitcoin is approaching its highest level in more than a year after soaring above the $11,000 level this weekend.Bitcoinread more
Pfizer shares have been lagging the market this year. But the stock's fortunes will improve, according to one big Wall Street firm.
Morgan Stanley raised its rating for Pfizer shares to overweight from equal-weight Wednesday, predicting strong performance from one of the company's cancer drugs.
"We believe investors underappreciate the global prospects for Pfizer's #1 growth driver Ibrance (breast cancer)," analyst David Risinger wrote in a note to clients. "We expect Ibrance to maintain its first-to-market advantage."